Search
for
Sort by
Research 421–450 of 477
- 0036 IL-27 generates immunosuppressive CD4 T cells and and prevents the development of alopecia areata
- 455 Molecular correlation with clinical outcomes in an open label clinical trial of oral tofacitinib in patients with alopecia areata
- Possible Involvement of Skin‐Resident Memory T Cells in Refractory Chronic Alopecia Areata
- 022 Exploring the potential of the novel IFNγ aptamer TAGX-0003 as a treatment for alopeciaareata in pre-clinical models
- Translational Positioning of Janus Kinase (JAK) Inhibitors in Alopecia Areata
- Oral Tofacitinib and Systemic Corticosteroids, Alone or in Combination, in Patients With Moderate-to-Severe Alopecia Areata: A Retrospective Study
- 320 An open label clinical trial of Abatacept (CTLA4-Ig) for alopecia areata
- Hair follicles as immune targets: unraveling cellular players, cytokine crosstalk, and precision pathways for future therapy of alopecia areata
- Towards cell-based therapy of alopecia areata: Autologous human Vδ2+ Foxp3+ γδTreg cells restore hair-follicle immune privilege and promote hair regrowth in human alopecia areata models ex vivo and in vivo
- Tru9I Variant as a Novel Genetic Marker for Vitamin D Deficiency in Alopecia Areata
- Carotid Intima Media Thickness Measurement in Alopecia Areata Patients
- 001 Human scalp hair follicles are protected from alopecia areata in vivo by regulatory γδT cells
- 185 Regulatory γδ T cells protect human scalp hair follicles from alopecia areata in vivo
- Blocking Potassium Channels (Kv1.3): A New Treatment Option for Alopecia Areata?
- Clinical Efficacy and Safety of Baricitinib in Patients With Alopecia Areata in Korea
- PRP for Immune Mediated Alopecias (Alopecia Areata, Alopecia Totalis)
- High throughput T cell receptor sequencing identifies clonally expanded CD8+ T cell populations in Alopecia Areata
- Effectiveness and Safety Profile of Oral Tofacitinib in Alopecia Areata: An Observational Study from a Tertiary Hospital
- Role of Aire and Notch4 Allelic Mutations in Alopecia Areata in C3H/HeJ Mice
- Upadacitinib: A New Weapon for the Treatment of Twenty-Nail Dystrophy
- Alopecia Areata in Sub-Saharan Africa: A Scoping Review Protocol on Epidemiology, Clinical Presentation, Burden, Treatment, and Evidence Gaps.
- Unveiling the immune and vitamin profiles of blood: the potential biomarkers for alopecia areata
- Efficacy and safety of tofacitinib in patients with total and universal alopecia- A retrospective evaluation of 69 patients
- Alopecia areata treated using CO2 fractional laser with different parameters
- Comparative efficacy and safety of JAK inhibitors in the treatment of moderate-to-severe alopecia areata: a systematic review and network meta-analysis
- Upadacitinib for the treatment of alopecia areata – A case report
- 153 Effectiveness of OR-101, a next generation highly selective JAK3 inhibitor, in a humanized murine model of alopecia areata
- 27 Preclinical ex vivo and in vivo evidence supporting selective inhibition of tyrosine kinase 2-dependent, IL-12-mediated signaling as a novel pharmacological strategy for alopecia areata management
- 1406 Environmental pathobiology of frontal fibrosing alopecia (FFA): A link between linalool sensitization and FFA development
- 382 Environmental pathobiology of frontal fibrosing alopecia (FFA): Does linalool promote FFA development and progression by inducing epithelial hair follicle stem cell damage and MICA expression in the bulge?